



This quarter the **<u>UKSCB</u>** announces a number of new and exciting developments of interest regarding collaborative working towards gene therapy, stem cell therapy and tissue engineering:-

## > NIBSC signs agreement with UCL.

National Institute for Biological Standards and Control (NIBSC) and University College London (UCL) sign a Memorandum of Understanding (MOU), which brings together a significant combined force that will help to realize the tremendous promise of gene therapy, stem cell therapy and tissue engineering in preventing and treating illness, restoring health and saving lives. <u>Read more</u> ...



## UKSCB announces completion of due diligence process of the first 14 hESCs intended for human application.

The UKSCB has completed Due Diligence assessment of the first 14 UK embryonic stem cell lines intended for human application by their depositors. These have been assessed as complying with HTA directions allowing the UKSCB to accession and begin banking these cell lines. The first 6 of these have been accessioned by the bank and banking of these lines will commence shortly.

## Tokyo Electron Launches its Open Innovation Stem Cell Technology Centre (STC) in the UK to Develop Smart Cell Processing Technologies



Tokyo Electron Limited (TEL) opened, through its European subsidiary Tokyo Electron Europe Limited (TEE), the company's open innovation centre at Stevenage Bioscience Catalyst (SBC) in the United Kingdom. The goal is to work, with its ecosystem partners from academia and industry; develop standardised Smart Cell Processing Technologies for cell culture and characterisation through open innovation. TEL will also develop technologies to quantify and standardise cell quality with the National Institute for Biological Standards and Control (NIBSC), as well as stem cell researchers in UK academia. TEL ultimately aims to develop a vital platform for the UK cell therapy industry, working with ecosystem partners, such as the Cell Therapy Catapult and Roslin Cells. <u>Read</u> more...

- The UKSCB website is currently under transition and upgrade. Please be patient with us as we complete this essential piece of work. However you can still continue to keep in touch through our <u>enquiries</u> email and visit the <u>website</u> for more information on:
  - ✓ Placing an order for <u>human stem cell lines</u> and qualified mouse feeder cells (<u>QMEFs</u>);
  - EUTCD <u>qualification</u> of cell lines intended for clinical applications;
  - ✓ Obtaining information on <u>current Research & Development</u> at the UKSCB;
  - Exploring collaborative research and development towards <u>quality, safety and</u> <u>standardisation;</u>
  - Arrange a meeting with the <u>UKSCB team</u>.

This newsletter is sent to you from the UK Stem Cell Bank, Blanche Lane, South Mimms, Hertfordshire, EN6 3QG, UK. If you prefer not to receive any further newsletters from the UKSCB, please email us on enquires@ukstemcellbank.org with the subject 'Unsubscribe'